EP1534728A4 - Antisense-modulation der glucocorticoid-rezeptor-expression - Google Patents

Antisense-modulation der glucocorticoid-rezeptor-expression

Info

Publication number
EP1534728A4
EP1534728A4 EP03729073A EP03729073A EP1534728A4 EP 1534728 A4 EP1534728 A4 EP 1534728A4 EP 03729073 A EP03729073 A EP 03729073A EP 03729073 A EP03729073 A EP 03729073A EP 1534728 A4 EP1534728 A4 EP 1534728A4
Authority
EP
European Patent Office
Prior art keywords
glucocorticoid receptor
receptor expression
antisense modulation
expression
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03729073A
Other languages
English (en)
French (fr)
Other versions
EP1534728A2 (de
Inventor
Seth D Crosby
Amy E Nalseth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of EP1534728A2 publication Critical patent/EP1534728A2/de
Publication of EP1534728A4 publication Critical patent/EP1534728A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03729073A 2002-05-20 2003-05-20 Antisense-modulation der glucocorticoid-rezeptor-expression Withdrawn EP1534728A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38185702P 2002-05-20 2002-05-20
US381857P 2002-05-20
PCT/US2003/016084 WO2003099215A2 (en) 2002-05-20 2003-05-20 Antisense modulation of glucocorticoid receptor expression

Publications (2)

Publication Number Publication Date
EP1534728A2 EP1534728A2 (de) 2005-06-01
EP1534728A4 true EP1534728A4 (de) 2005-10-26

Family

ID=29584332

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03729073A Withdrawn EP1534728A4 (de) 2002-05-20 2003-05-20 Antisense-modulation der glucocorticoid-rezeptor-expression

Country Status (4)

Country Link
EP (1) EP1534728A4 (de)
JP (1) JP2005525829A (de)
AU (1) AU2003233634A1 (de)
WO (1) WO2003099215A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005071080A2 (en) * 2004-01-20 2005-08-04 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
WO2006034348A2 (en) * 2004-09-17 2006-03-30 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
EP2368988A1 (de) * 2005-09-19 2011-09-28 Isis Pharmaceuticals, Inc. Modulierung der Glukokortikoid-Rezeptor-Expression
WO2007143315A2 (en) 2006-05-05 2007-12-13 Isis Pharmaceutical, Inc. Compounds and methods for modulating expression of pcsk9
JP2009171895A (ja) * 2008-01-24 2009-08-06 Hitachi Software Eng Co Ltd 核内ノンコーディングｒｎａの機能解析方法
CA2759838A1 (en) * 2009-05-15 2010-11-18 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes
EP2545173A2 (de) * 2010-03-12 2013-01-16 Sarepta Therapeutics, Inc. Antisense-modulation von nukleären hormonrezeptoren
KR20140084232A (ko) 2011-10-25 2014-07-04 아이시스 파마수티컬즈 인코포레이티드 Gccr 발현의 안티센스 조절
US9234200B2 (en) * 2011-12-15 2016-01-12 National University Of Corporation Tokyo University Of Agriculture And Technology Oligonucleotide, glucocorticoid sensitivity enhancer, pharmaceutical composition, and expression vector
US10364433B2 (en) * 2014-11-14 2019-07-30 The Regents Of The University Of California Modulation of AGPAT5 expression
SG11202011146TA (en) * 2018-05-17 2020-12-30 Univ Minnesota Drug-resistant immune cells and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027986A1 (en) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027986A1 (en) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
29TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE.; MIAMI BEACH, FLORIDA, USA; OCTOBER 23-28, 1999 *
ALTMANN K-H ET AL: "NOVEL CHEMISTRY", APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, NEW YORK, WILEY-LISS, US, 1998, pages 73 - 107, XP002119324, ISBN: 0-471-17279-0 *
HOLLENBERG S M ET AL: "PRIMARY STRUCTURE AND EXPRESSION OF A FUNCTIONAL HUMAN GLUCOCORTICOID RECEPTOR CDNA", NATURE, vol. 318, 19 December 1985 (1985-12-19), pages 635 - 641, XP000611470, ISSN: 0028-0836 *
ISLAM A ET AL: "Antisense oligodeoxynucleotide to rat glucocorticoid receptor, given ICV in polymer microspheres, reduces glucocorticoid- and increases 5-HT2A-receptor binding", BRITISH JOURNAL OF PHARMACOLOGY, vol. 129, no. Proceedings Supplement, January 2000 (2000-01-01), pages 244P, XP008051733, ISSN: 0007-1188 *
ISLAM A ET AL: "Antisense oligonucleotides to the rat glucocorticoid receptor (GR), optimised by RNase-H accessibility mapping of in vitro transcribed mRNA, modulate GR and 5-HT2A expression in C6 glioma cells", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 25, no. 1-2, 1999, pages 1817, XP008051792, ISSN: 0190-5295 *
MEETING OF THE BRITISH PHARMACOLOGICAL SOCIETY; CAMBRIDGE, ENGLAND, UK; JANUARY 05-07, 2000. *
RICHARDS D ET AL: "Energy balance and lipid metabolism in transgenic mice bearing an antisense GCR gene construct", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 265, no. 1 PART 2, 1993, pages R146 - R150, XP008051596, ISSN: 0002-9513 *

Also Published As

Publication number Publication date
WO2003099215A2 (en) 2003-12-04
JP2005525829A (ja) 2005-09-02
WO2003099215A3 (en) 2005-03-31
EP1534728A2 (de) 2005-06-01
AU2003233634A8 (en) 2003-12-12
AU2003233634A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2004030750A8 (en) Antisense modulation of farnesoid x receptor expression
WO2003012057A3 (en) Antisense modulation of serum amyloid a4 expression
AU2001290706A1 (en) Antisense modulation of clusterin expression
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
WO2004071407A3 (en) Antisense modulation of ptp1b expression
WO2003052072A3 (en) Antisense modulation of estrogen receptor alpha expression
EP1409509A4 (de) Antisense-modulation der expression von c-reactive-protein
WO2003099215A3 (en) Antisense modulation of glucocorticoid receptor expression
EP1212456A4 (de) Antisense modulation der shp-2 expression
WO2003000656A3 (en) Antisense modulation of transforming growth factor beta receptor ii expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2003057843A3 (en) Methods and materials for modulating trpc4
WO2003104397A3 (en) ANTISENSE MODULATION OF PROTEIN KINASE GR 6 EXPRESSION
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2003088921A3 (en) Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
WO2003050244A3 (en) Antisense modulation of g protein-coupled receptor etbr-lp-2 expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2003057847A8 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2004016749A3 (en) Antisense modulation of acyl-coa synthetase 1 expression
WO2004003201A3 (en) Antisense modulation of lrh1 expression
WO2004011623A3 (en) Antisense modulation of ptpra expression
WO2004015126A3 (en) Antisense modulation of edg1 expression
WO2003031576A3 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20050909

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/11 A

Ipc: 7A 61K 31/7088 B

Ipc: 7C 07H 21/00 B

Ipc: 7A 61P 3/00 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051124